Phase 2 Phenylketonuria Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 to 75 years, of any gender, may be considered for this trial
- People who have been clinically diagnosed with PKU (phenylketonuria) may be eligible
- Participants must be willing and able to keep their diet and protein intake consistent throughout the study
- For certain study groups, participants may need to be willing and able to stop certain PKU medications before the study treatment begins
- For certain study groups, additional requirements around blood phenylalanine levels or current background treatments may apply (confirm with trial site)
- Blood phenylalanine levels must meet a minimum threshold for the relevant study group (confirm with trial site)
Who may not be able to join:
- People who are pregnant, breastfeeding, planning to become pregnant, or planning to father a child during the study or within 90 days after the last dose may not be eligible
- People with certain medical conditions or abnormal test results that could make participation unsafe, or that could interfere with completing study procedures or interpreting results, may not be eligible
- People who have recently received another investigational (experimental) drug may not be eligible
- People who are unable to swallow tablets or tolerate medication taken by mouth may not be eligible
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Maze Therapeutics
Phone: 650-850-5075
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and tolerability based on incidence of adverse events (AEs); For Cohorts 1A and 1B: Absolute change in plasma Phe levels from Baseline to the mean of plasma Phe levels
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.